Epidermal growth factor receptor as a therapeutic target in head and neck cancer

Seminars in Radiation Oncology

Volumn 12, Issue 3 SUPPL. 2, 2002, Pages 11-20

  Bonner, James A ^a   De Los Santos, Jennifer ^a   Waksal, Harlan W ^a   Needle, Michael N ^a   Trummel, Hoa Q ^a   Raisch, Kevin P ^a  

^a The University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CELL MEMBRANE PROTEIN; CETUXIMAB; CISPLATIN; COMPLEMENTARY DNA; DOXORUBICIN; EMD 55900; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROURACIL; STAT3 PROTEIN; TRANSFORMING GROWTH FACTOR ALPHA; VINBLASTINE;

APOPTOSIS; ASTHENIA; CELL PROLIFERATION; CLINICAL TRIAL; DRUG HYPERSENSITIVITY; FLOW CYTOMETRY; GENE MUTATION; GROWTH INHIBITION; HEAD AND NECK CANCER; HUMAN; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MUCOSA INFLAMMATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RADIOSENSITIZATION; REVIEW; SIGNAL TRANSDUCTION; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA;

EID: 0036638328     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1053/srao.2002.34864     Document Type: Review

References (51)

1. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer
2. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival
3. Blockade of receptors for growth factors: An anticancer therapy - The fourth annual Joseph H. Burchenal American Association for Cancer Research Clinical Research Award Lecture
4. The Willet F. Whitmore Jr., lectureship: Blockade of epidermal growth factor receptors as anticancer therapy
5. The EGF receptor family as targets for cancer therapy
6. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas
7. Potential indicators of radiosensitivity in squamous cell carcinoma of the head and neck
8. Increased resistance to cytotoxic agents in ZR 75B human breast cancer cells transfected with epidermal growth factor receptor
9. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: A review on 5232 patients
10. Characterization, quantification, and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas
11. Immunohistochemical study of glutathione-related enzymes and proliferative antigens in lung cancer. Relation to cisplatin sensitivity
12. Expression of resistance factor (P-glycoprotein, glutathione S-transferase-pi, and topoisomerase II) and their interrelationship to proto-oncogene products in renal cell carcinomas
13. EGFR and steroid receptors in ovarian carcinoma: Comparison with prognostic parameters and outcome of patients
14. Oncogene alterations in carcinomas of the uterine cervix: Overexpression of the epidermal growth factor receptor is associated with poor prognosis
15. Clinical implications of the epidermal growth factor receptor in the squamous cell carcinoma of the uterine cervix
16. Expression of epidermal growth factor receptor in carcinoma of the cervix
17. Evaluation of the prognostic significance of cathepsin D, epidermal growth factor receptor, and c-erbB-2 in early cervical squamous cell carcinoma. An immunohistochemical study
18. Epidermal growth factor receptor (EGFR) is not related to the prognosis of cervical cancer
19. Multiparameter flow-cytometric quantitation of epidermal growth factor receptor and c-erbB-2 oncoprotein in normal and neoplastic tissues of the female genital tract
20. The expression of EGF receptors, EGF-like factors and c-myc in ovarian and cervical carcinomas and their potential clinical significance
21. Expression of ras oncogene product of EGF receptor in cervical squamous cell carcinomas and its relationship to lymph node involvement
22. Prognostic value of epidermal growth factor receptor expression in cervical carcinoma
23. Epidermal growth factor receptor expression in gynecological malignancies
24. Quantitative determination of the epidermal growth factor receptor in cervical cancer and normal cervical epithelium by 2-color flow cytometry: Evidence for down-regulation in cervical cancer
25. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas
26. Amplification of the structurally and functionally altered epidermal growth factor receptor gene (c-erbB) in human brain tumors
27. Structural alterations of the epidermal growth factor receptor gene in human gliomas
28. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails
29. The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy
30. Antitumor activity of anti-epidermal growth factor receptor monoclonal antibodies and cisplatin in ten human head and neck squamous cell carcinoma lines
31. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells
32. Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers
33. The interaction of epidermal growth factor and radiation in two human squamous cell carcinoma cell lines with vastly different radiosensitivities
34. Ionizing radiation-induced MEK and Erk activation does not enhance survival or irradiated human squamous carcinoma cells
35. Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation
36. Reversible G(1) arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27 (KIP1) independent of MAPK activity
37. STAT3 mediates the survival signal in oncogenic ras-transfected intestinal epithelial cells
38. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors
39. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice
40. Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice
41. A central role of Bcl-X(L) in the regulation of keratinocyte survival by autocrine EGFR ligands
42. Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3′-kinase and distinct from that induced by hypoxia
43. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer
44. C225 antiepidermal growth factor receptor antibody enhances tumor radiocurability
45. The effect of ionizing radiation on signal transduction: Antibodies to EGF receptor sensitize A 431 cells to radiation
46. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody
47. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck
48. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin
49. Continued response following treatment with IMC-C225, and EGFr MoAb, combined with RT in advanced head and neck malignancies
50. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer